Swiss National Bank Sells 32,400 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Swiss National Bank lowered its position in Amicus Therapeutics, Inc. (NASDAQ:FOLDGet Rating) by 6.1% in the second quarter, Holdings Channel.com reports. The institutional investor owned 494,700 shares of the biopharmaceutical company’s stock after selling 32,400 shares during the period. Swiss National Bank’s holdings in Amicus Therapeutics were worth $5,313,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. JPMorgan Chase & Co. increased its position in shares of Amicus Therapeutics by 1.4% in the 1st quarter. JPMorgan Chase & Co. now owns 15,551,816 shares of the biopharmaceutical company’s stock valued at $147,275,000 after buying an additional 207,988 shares in the last quarter. State Street Corp increased its holdings in Amicus Therapeutics by 13.6% during the 1st quarter. State Street Corp now owns 11,934,563 shares of the biopharmaceutical company’s stock worth $113,020,000 after purchasing an additional 1,432,498 shares in the last quarter. Fiera Capital Corp increased its holdings in Amicus Therapeutics by 3.9% during the 1st quarter. Fiera Capital Corp now owns 4,156,748 shares of the biopharmaceutical company’s stock worth $39,365,000 after purchasing an additional 155,907 shares in the last quarter. William Blair Investment Management LLC increased its holdings in Amicus Therapeutics by 2.2% during the 1st quarter. William Blair Investment Management LLC now owns 2,531,412 shares of the biopharmaceutical company’s stock worth $23,972,000 after purchasing an additional 54,691 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Amicus Therapeutics by 2.4% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,004,734 shares of the biopharmaceutical company’s stock worth $18,985,000 after purchasing an additional 47,117 shares in the last quarter.

Insider Transactions at Amicus Therapeutics

In other news, Chairman John F. Crowley sold 11,346 shares of the stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $10.75, for a total transaction of $121,969.50. Following the completion of the transaction, the chairman now directly owns 845,551 shares in the company, valued at approximately $9,089,673.25. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, Chairman John F. Crowley sold 11,346 shares of the stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $10.75, for a total transaction of $121,969.50. Following the completion of the transaction, the chairman now directly owns 845,551 shares in the company, valued at approximately $9,089,673.25. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Chairman John F. Crowley sold 10,468 shares of the stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $11.64, for a total transaction of $121,847.52. Following the transaction, the chairman now owns 813,269 shares of the company’s stock, valued at $9,466,451.16. The disclosure for this sale can be found here. Insiders sold a total of 65,036 shares of company stock worth $698,952 in the last three months. Insiders own 2.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Morgan Stanley increased their target price on Amicus Therapeutics from $14.00 to $15.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 8th. StockNews.com upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, November 8th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $14.67.

Amicus Therapeutics Trading Down 1.0 %

Amicus Therapeutics stock opened at $11.43 on Friday. The firm has a 50-day moving average of $10.70 and a 200-day moving average of $10.30. Amicus Therapeutics, Inc. has a one year low of $5.91 and a one year high of $12.96. The company has a debt-to-equity ratio of 2.95, a current ratio of 2.78 and a quick ratio of 2.70. The company has a market cap of $3.21 billion, a price-to-earnings ratio of -12.42 and a beta of 0.85.

Amicus Therapeutics Company Profile

(Get Rating)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.

Featured Articles

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLDGet Rating).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.